| 标题： | 医疗机构国家医保谈判药品管理中国专家共识 |
| title： | Consensus of Chinese experts on the management of national medical insurance negotiation drug in medical institutions |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 管理 |
| field： | Administration |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 各级各类医疗机构的药师、医师等相关医务人员，卫生行政及医疗保障主管部门的管理人员。 |
| Guide users： | Pharmacists, physicians, and other related medical personnel, as well as managers of health administration and medical security authorities in medical institutions of all levels and types |
| 证据分级方法： | 本专家共识的证据来源主要为各类研究文献，采用 GRADE（Grades of Recommendation，Assessment，Development，and Evaluation）方法评价问题证据体系的质量。部分证据来源主要为国家相关部门文件，按照《立法法》进行证据分级。由于本专家共识所基于的文献证据以非经典证据为主，因此在评价过程中，将综合考虑证据类型，对非经典证据不采用针对经典研究证据的质量评价工具进行证据质量评价。 |
| Evidence grading method： | The evidence sources of this expert consensus are mainly various research literatures. GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) method is adopted to evaluate the quality of the evidence system. Some evidence sources are mainly documents from relevant national departments, and the evidence is graded according to the Legislation Law. Since the literature evidence based on this expert consensus is mainly non-classical evidence, the type of evidence will be comprehensively considered in the evaluation process, and the quality evaluation tools for classical research evidence will not be used to evaluate the quality of evidence for non-classical evidence. |
| 制定单位： | 中国药师协会精准药学工作委员会 |
| Formulating unit： | Precision Pharmacy Working Committee of Chinese Pharmacists Association |
| 注册时间： | 2024-08-01 |
| Registration time： | |
| 注册编号： | PREPARE-2024CN098 |
| Registration number： | |
| 指南制订的目的： | 本专家共识是基于法律法规相关规定及可获得的最佳证据制定而成，主要基于医疗机构落地谈判药品的全流程，重点关注医疗机构谈判药品准入与临床应用管理的现状，以患者为中心，为保障临床合理使用谈判药品提供精益化管理措施与指导性建议，实现医疗机构谈判药品全链条精益化管理。 |
| Purpose of the guideline： | This expert consensus is formulated based on relevant provisions of laws and regulations as well as the best available evidence, mainly focusing on the whole process of landing negotiated drugs in medical institutions. It highlights the current status of negotiated drug access and clinical application management in medical institutions. Centered on patients, it provides lean management measures and guiding suggestions to ensure the rational use of negotiated drugs in clinical practice, and achieves the lean management of the whole chain of negotiating drugs in medical institutions. |
